Signature Estate & Investment Advisors LLC Cuts Holdings in Danaher Corporation $DHR

Signature Estate & Investment Advisors LLC decreased its stake in shares of Danaher Corporation (NYSE:DHR) by 9.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,520 shares of the conglomerate’s stock after selling 167 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Danaher were worth $300,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Hills Bank & Trust Co increased its holdings in shares of Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock valued at $3,693,000 after acquiring an additional 53 shares during the last quarter. Worth Financial Advisory Group LLC increased its holdings in shares of Danaher by 4.6% in the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after acquiring an additional 53 shares during the last quarter. Sageworth Trust Co increased its holdings in shares of Danaher by 2.3% in the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock valued at $493,000 after acquiring an additional 54 shares during the last quarter. 1834 Investment Advisors Co. increased its holdings in shares of Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 54 shares during the last quarter. Finally, Bruce G. Allen Investments LLC increased its holdings in shares of Danaher by 13.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after acquiring an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $208.06 on Tuesday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $274.21. The company has a market cap of $148.98 billion, a price-to-earnings ratio of 44.27, a price-to-earnings-growth ratio of 2.98 and a beta of 0.77. The stock has a 50 day simple moving average of $201.76 and a 200-day simple moving average of $197.42. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the business posted $1.72 EPS. Danaher’s quarterly revenue was up 3.4% on a year-over-year basis. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on DHR shares. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective on the stock in a report on Friday, July 11th. UBS Group decreased their target price on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. Bank of America decreased their target price on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Barclays reissued an “overweight” rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Finally, Evercore ISI upped their target price on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $245.00.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 11.20% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.